PALI ▲ +3.6% - Palisade Bio, Inc. $PALI - Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD Palisade Bio shares rose 3.6% following the company's announcement that the FDA has cleared an Investigational New Drug application for PALI-2108 in Crohn's disease, allowing the company to expand Phase 2 testing across inflammatory bowel disease indications. The IND clearance represents regulatory progress for the candidate and validates the company's approach to treating IBD, supporting investor optimism about the program's development trajectory. 22-SEP-2026 08:35 AM ET